# Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Study · id `cardio:ct-nct02099110` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02099110](<https://clinicaltrials.gov/study/NCT02099110>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02099110

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1233 participants.

## Technical summary

Registry record NCT02099110. Randomized; double masking; primary purpose treatment. Start 2014-04-22 (actual); primary completion 2016-05-26 (actual). Results posted on 2017-11-01.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1233 participants (enrolled count; ClinicalTrials.gov record NCT02099110, source copy `cardio:ctgov-nct02099110-2018-09-12`, retrieved 2026-10-26)
- Started: 2014-04-22 (actual) (ClinicalTrials.gov record NCT02099110, source copy `cardio:ctgov-nct02099110-2018-09-12`, retrieved 2026-10-26)
- Primary completion: 2016-05-26 (actual) (ClinicalTrials.gov record NCT02099110, source copy `cardio:ctgov-nct02099110-2018-09-12`, retrieved 2026-10-26)
- Completion: 2016-05-26 (actual) (ClinicalTrials.gov record NCT02099110, source copy `cardio:ctgov-nct02099110-2018-09-12`, retrieved 2026-10-26)
- Results first posted: 2017-11-01 (ClinicalTrials.gov record NCT02099110, source copy `cardio:ctgov-nct02099110-2018-09-12`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02099110-2018-09-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Matching Placebo to Ertugliflozin 5 mg
- Intervention (Drug): Matching Placebo to Ertugliflozin 10 mg
- Intervention (Drug): Matching Placebo to sitagliptin 100 mg
- Intervention (Drug): Ertugliflozin 5 mg
- Intervention (Drug): Ertugliflozin 10 mg
- Intervention (Drug): Sitagliptin 100 mg
- Intervention (Drug): Metformin &gt;= 1500 mg/day
- Intervention (Biological): Insulin Glargine Rescue Medication
- Intervention (Drug): Glimepiride Rescue Medication
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial (`cardio:pubmed-29266675`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 10eaef35b6c7cf829acdc93ed150d1676115e8d8dbdf0a81efd20fc6e867c99a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
